Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women

Gynecologic Oncology

Volumn 125, Issue 3, 2012, Pages 667-672

  Hallamaa, M ^a   Suvitie, P ^a   Huhtinen, K ^a,b   Matomaki J ^a   Poutanen, M ^b   Perheentupa, A ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Biomarker; CA125; HE4; Hormonal treatment; Menstrual cycle

Indexed keywords

AROMATASE INHIBITOR; CA 125 ANTIGEN; EPIDIDYMAL SECRETORY PROTEIN; ESTROGEN; GESTAGEN; GONADORELIN DERIVATIVE; HUMAN EPIDIDYMAL SECRETORY PROTEIN E4; UNCLASSIFIED DRUG;

ADULT; BODY MASS; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL PRACTICE; CONFERENCE PAPER; CONTRACEPTION; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SENSITIVITY ANALYSIS;

ADULT; AROMATASE INHIBITORS; CA-125 ANTIGEN; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, COMBINED; ENDOMETRIOSIS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONES; HUMANS; MEMBRANE PROTEINS; MENSTRUAL CYCLE; MIDDLE AGED; PREMENOPAUSE; PROGESTINS; PROTEINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84861193944     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.03.011     Document Type: Conference Paper

References (42)

1. J.M. Niloff, R.C. Knapp, P.T. Lavin, G.D. Malkasian, J.S. Berek, R. Mortel, C. Whitney, V.R. Zurawski, and R.C. Bast The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer Am J Obstet Gynecol 155 1986 56 60
2. S. Kabawat, R. Bast, W. Welch, R. Knapp, and R. Colvin Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types Am J Clin Pathol 79 1983 98 104
3. H. Meden, and A. Fattahi-Meibodi CA 125 in benign gynecological conditions Int J Biol Markers 13 1998 213 217
4. R.J. Bast, T. Klug, E. St John, E. Jenison, J. Niloff, H. Lazarus, R. Berkowitz, T. Leavitt, C. Griffiths, L. Parker, V.J. Zurawski, and R. Knapp A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N Engl J Med 309 1983 883 887
5. L. Fedele, P. Vercellini, L. Arcaini, M. da Dalt, and G. Candiani CA 125 in serum, peritoneal fluid, active lesions, and endometrium of patients with endometriosis Am J Obstet Gynecol 158 1988 166 170
6. D. Pittaway, and J. Fayez The use of CA-125 in the diagnosis and management of endometriosis Fertil Steril 46 1986 790 795
7. I. Jacobs, I. Stabile, J. Bridges, P. Kemsley, C. Reynolds, J. Grudzinskas, and D. Oram Multimodal approach to screening for ovarian cancer Lancet 1 1988 268 271
8. R.J. Bast, Y. Badgwell, Z. Lu, R. Marquez, D. Rosen, J. Liu, K. Baggerly, E. Atkinson, S. Skates, Z. Zhang, A. Lokshin, U. Menon, I. Jacobs, and K. Lu New tumor markers: CA125 and beyond Int J Gynecol Cancer 15 Suppl 3 2005 274 281
9. S. Sato, Y. Yokoyama, T. Sakamoto, M. Futagami, and Y. Saito Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography Cancer 89 2000 582 588
10. J.J. van Nagell, P. DePriest, M. Reedy, H. Gallion, F. Ueland, E. Pavlik, and R. Kryscio The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer Gynecol Oncol 77 2000 350 356
11. Z. Yurkovetsky, S. Skates, A. Lomakin, B. Nolen, T. Pulsipher, F. Modugno, J. Marks, A. Godwin, E. Gorelik, I. Jacobs, U. Menon, K. Lu, D. Badgwell, R.J. Bast, and A. Lokshin Development of a multimarker assay for early detection of ovarian cancer J Clin Oncol 28 2010 2159 2166
12. B. Nolen, L. Velikokhatnaya, A. Marrangoni, K. De Geest, A. Lomakin, R.J. Bast, and A. Lokshin Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass Gynecol Oncol 117 3 2010 440 445
13. I. Jacobs, D. Oram, J. Fairbanks, J. Turner, C. Frost, and J. Grudzinskas A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer Br J Obstet Gynaecol 97 1990 922 929
14. R. Moore, M. Jabre-Raughley, A. Brown, K. Robison, M. Miller, W. Allard, R. Kurman, R. Bast, and S. Skates Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass Am J Obstet Gynecol 203 3 2010 228.e1 228.e6
15. I. Hellström, J. Raycraft, M. Hayden-Ledbetter, J. Ledbetter, M. Schummer, M. McIntosh, C. Drescher, N. Urban, and K. Hellström The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma Cancer Res 63 2003 3695 3700
16. M. Galgano, G. Hampton, and H.J. Frierson Comprehensive analysis of HE4 expression in normal and malignant human tissues Mod Pathol 19 2006 847 853
17. L. Havrilesky, C. Whitehead, J. Rubatt, R. Cheek, J. Groelke, Q. He, D. Malinowski, T. Fischer, and A. Berchuck Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence Gynecol Oncol 110 2008 374 382
18. E. Anastasi, G. Marchei, V. Viggiani, G. Gennarini, L. Frati, and M. Reale HE4: a new potential early biomarker for the recurrence of ovarian cancer Tumour Biol 31 2010 113 119
19. K. Huhtinen, P. Suvitie, J. Hiissa, J. Junnila, J. Huvila, H. Kujari, M. Setälä, P. Härkki, J. Jalkanen, J. Fraser, J. Mäkinen, A. Auranen, M. Poutanen, and A. Perheentupa Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts Br J Cancer 100 2009 1315 1319
20. M. Montagnana, G. Lippi, O. Ruzzenente, V. Bresciani, E. Danese, S. Scevarolli, G. Salvagno, S. Giudici, M. Franchi, and G. Guidi The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass J Clin Lab Anal 23 2009 331 335
21. K. Lowe, C. Shah, E. Wallace, G. Anderson, P. Paley, M. McIntosh, M. Andersen, N. Scholler, L. Bergan, J. Thorpe, N. Urban, and C. Drescher Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer Cancer Epidemiol Biomarkers Prev 17 2008 2480 2487
22. R. Moore, A. Brown, M. Miller, S. Skates, W. Allard, T. Verch, M. Steinhoff, G. Messerlian, P. DiSilvestro, C. Granai, and R.J. Bast The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol Oncol 108 2008 402 408
23. H. Kafali, H. Artunc, and M. Erdem Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle Arch Gynecol Obstet 275 2007 175 177
24. A. Erbaǧci, N. Yilmaz, and I. Kutlar Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women Dis Markers 15 1999 259 267
25. G. Bon, P. Kenemans, J. Dekker, P. Hompes, R. Verstraeten, G. van Kamp, and J. Schoemaker Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles Hum Reprod 14 1999 566 570
26. I. Matalliotakis, A. Arici, A. Goumenou, T. Katassos, N. Karkavitsas, and E. Koumantakis Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA-125 levels in women with endometriosis Int J Fertil Womens Med 49 2004 75 78
27. A. de Sá Rosa e Silva, J. Rosa e Silva, A. Nogueira, C. Petta, M. Abrão, and R. Ferriani The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis Fertil Steril 86 2006 742 744
28. E. Anastasi, T. Granato, G. Marchei, V. Viggiani, B. Colaprisca, S. Comploj, M. Reale, L. Frati, and C. Midulla Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women Tumour Biol 31 5 2010 411 415
29. S. Kadija, A. Stefanovic, K. Jeremic, M.M. Radojevic, L. Nikolic, I. Markovic, and J. Atanackovic The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis Int J Gynecol Cancer 22 2012 238 244
30. R.G. Moore, M.C. Miller, M.M. Steinhoff, S.J. Skates, K.H. Lu, G. Lambert-Messerlian, and R.C. Bast Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders Am J Obstet Gynecol 206 2012 xx-xx
31. Revised American Society for Reproductive Medicine classification of endometriosis Fertil Steril 67 1997 817 821
32. I. Hellstrom, and K.E. Hellstrom fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma Expert Opin Med Diagn 5 2011 227 240
33. R.C. Bast Status of tumor markers in ovarian cancer screening J Clin Oncol 21 2003 200s 205s
34. B.J. Rein, S. Gupta, R. Dada, J. Safi, C. Michener, and A. Agarwal Potential markers for detection and monitoring of ovarian cancer J Oncol 2011 2011 475983
35. N. Bolstad, M. Oijordsbakken, K. Nustad, and J. Bjerner Human epididymis protein 4 reference limits and natural variation in a Nordic reference population Tumour Biol 33 1 2012 141 148
36. Y.Y. Kan, S.H. Yeh, H.T. Ng, and C.M. Lou Effect of menstruation on serum CA125 levels Asia Oceania J Obstet Gynaecol 18 1992 339 343
37. D.E. Pittaway, and J.A. Fayez Serum CA-125 antigen levels increase during menses Am J Obstet Gynecol 156 1987 75 76
38. J. Kitawaki, H. Ishihara, H. Koshiba, M. Kiyomizu, M. Teramoto, Y. Kitaoka, and H. Honjo Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas Hum Reprod 20 2005 1999 2003
39. Y. Haga, K. Sakamoto, H. Egami, R. Yoshimura, and M. Akagi Evaluation of serum CA125 values in healthy individuals and pregnant women Am J Med Sci 292 1986 25 29
40. T. Alagoz, R.E. Buller, M. Berman, B. Anderson, A. Manetta, and P. DiSaia What is a normal CA125 level? Gynecol Oncol 53 1994 93 97
41. A.W. Menzin, S. Kobrin, E. Pollak, D.B. Goodman, and S.C. Rubin The effect of renal function on serum levels of CA 125 Gynecol Oncol 58 1995 375 377
42. H. Kafali, H. Artuc, and N. Demir Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary report Eur J Obstet Gynecol Reprod Biol 116 2004 85 88